Welcome to our dedicated page for DarioHealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on DarioHealth stock.
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
DarioHealth's holistic approach offers continuous and customized care, disrupting the traditional episodic approach to healthcare. The company empowers people to adapt their lifestyles for sustainable behavior change, driving exceptional satisfaction, retention, and results. Dario's solutions are globally available to health plans, self-insured employers, care providers, and consumers.
One of DarioHealth's latest achievements includes the acquisition of Twill, Inc., a move that nearly doubles its pro forma revenues for 2023 and enhances its ability to deliver comprehensive digital health solutions. The integration of Twill is expected to create immediate scale, boost gross margins to approximately 80-85% by 2025, and accelerate the path to profitability through significant cost synergies.
Recent news highlights include Dario's partnership with Blue Shield of California to make its award-winning digital health platform, Wellvolution, more accessible to Spanish speakers. This initiative aims to close care gaps in underserved communities by offering personalized solutions for hypertension, diabetes, weight management, and mental health support. Additionally, Dario announced a new contract to provide its cardiometabolic solution to a regional union, further expanding its presence in the public and labor sectors.
DarioHealth's clinical research continuously demonstrates the efficacy of its digital solutions. For instance, a recent study published in the Journal of Internet Medicine (JMIR) showed significant reductions in blood glucose levels and BMI for members using Dario's weight monitoring features. Other studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes highlighted the company's ability to deliver improved health outcomes through integrated solutions.
Financially, DarioHealth reported strong performance in Q1 2024, with revenues of $5.8 million driven by growth in its Business-to-Business-to-Consumer (B2B2C) model. The company continues to launch new customer partnerships and expects further revenue growth throughout 2024.
With a strong cash position and ongoing innovation, DarioHealth is well-prepared to execute its strategy and solidify its leadership in the digital health space.
DarioHealth Corp. (Nasdaq: DRIO) announced new research in Pain Reports showing that personalized digital therapeutics can effectively reduce back pain. The study analyzed data from 3,610 users over three weeks, revealing significant pain reduction linked to a posture training program enhanced by machine learning. This personalized approach is crucial for optimizing user experiences and promoting ongoing engagement with digital health solutions. Dario aims to empower users through customized interventions, transforming chronic condition management.
DarioHealth Corp. (Nasdaq: DRIO) reported a significant financial turnaround for 2022, with total revenue reaching $27.7 million, marking a 34.8% increase from 2021. The pivot towards a B2B model drove commercial revenue, contributing 59% to total revenue. The operating loss in Q4 2022 dropped to $9 million, a 58% decrease compared to Q4 2021. Cash reserves stood at $49.3 million. Dario achieved over 100 B2B contracts, with total signed value surpassing $65 million. The company anticipates ongoing financial improvement, targeting gross margins of approximately 70% as its multi-condition platform gains traction.
DarioHealth Corp. (NASDAQ: DRIO) will announce its fourth quarter and full year 2022 financial results on March 9, 2023, before the market opens. A conference call and webcast will follow at 8:30 am ET. The call will feature CEO Erez Raphael, President Rick Anderson, and CFO Zvi Ben-David. Participants can join by dialing 1-877-451-6152 for domestic calls or 1-201-389-0879 for international. A replay will be available post-call, with further details accessible via the provided webcast link. DarioHealth specializes in digital therapeutics, focusing on personalized health solutions for chronic conditions.
DarioHealth Corp. (Nasdaq: DRIO) presented two clinical studies at the ATTD 2023 conference, highlighting its digital-first chronic care solution's effectiveness. One study focused on Type 2 diabetes, demonstrating an 18% reduction in blood glucose levels among users engaged with a coach compared to 11% for those without coaching. The second study revealed that older adults experienced a 31% reduction in level 1 hypoglycemic events and a 53% reduction in level 2 events after 6 months of using Dario's platform. These results emphasize the potential of combining human coaching with digital interventions for improved health outcomes.
DarioHealth Corp. (Nasdaq: DRIO) announced its participation in the Cowen 43rd Annual Healthcare Conference, scheduled for March 6-8, 2023, at the Boston Marriott Copley Place. CEO Erez Raphael and President Rick Anderson will engage in a fireside chat on March 6 from 10:30 to 11:00 AM ET. A live webcast will be available at this link and on DarioHealth's Investor Relations website, with a replay accessible for 90 days post-event. DarioHealth specializes in digital therapeutics, addressing chronic conditions through a comprehensive AI-powered platform.
DarioHealth Corp. (Nasdaq: DRIO) announced the appointment of Jon Kaplan as a board member. Kaplan, a Senior Partner at Boston Consulting Group, brings extensive experience in healthcare strategy and transformation. His previous advisory roles at digital health companies enhance his credentials. CEO Erez Raphael expressed confidence in Kaplan's ability to foster strategic relationships for long-term growth. Kaplan highlighted the company's timely shift towards multi-chronic digital healthcare amidst growing demand for scalable solutions. This appointment is seen as pivotal for Dario's future in the digital therapeutics market.
DarioHealth Corp. (Nasdaq: DRIO) has announced a partnership with Dexcom (Nasdaq: DXCM) to integrate continuous glucose monitoring (CGM) data into its digital therapeutics platform. This integration aims to enhance access to Dario's multi-chronic condition management solutions for diabetes patients. With nearly two million users of CGMs, the collaboration is expected to provide personalized support through real-time glucose data. This follows Dario's strategic agreement with Sanofi US, further expanding its digital health ecosystem. The initiative highlights Dario's commitment to enhancing the user experience and meeting market demand for integrated health solutions.
DarioHealth Corp. (NASDAQ: DRIO) announced preliminary unaudited revenue results for 2022, projecting total revenue of
DarioHealth Corp. (NASDAQ: DRIO) announced the hiring of Matt Alberico as Senior Vice President of Growth to accelerate growth opportunities in the digital therapeutics market. Alberico previously drove customer growth at Amazon Care, Cigna, and Aetna. His extensive sales strategy experience is expected to help Dario capitalize on increasing market demand for integrated health solutions, following the signing of their 100th contract. Additionally, Alberico received stock options totaling 100,000 shares at an exercise price of $5.97, vesting over a three-year period.
DarioHealth Corp. (Nasdaq: DRIO) announced new research published in Applied Sciences demonstrating improved diabetes outcomes across racial and ethnic groups. The study analyzed data from 1,000 Type 2 diabetes users over 12 months, showing a 14% reduction in average blood glucose for White users and a 15% reduction for Black, Latino, and Asian users. The findings indicate that Dario's digital therapeutics platform effectively engages users without racial disparities in outcomes and emphasizes the company's commitment to addressing health inequities through digital health solutions.
FAQ
What is the current stock price of DarioHealth (DRIO)?
What is the market cap of DarioHealth (DRIO)?
What is DarioHealth Corp.?
What recent achievements has DarioHealth made?
How does DarioHealth's platform work?
What clinical results support DarioHealth's solutions?
Who are DarioHealth's target customers?
What are the financial prospects for DarioHealth?
What is the significance of DarioHealth's acquisition of Twill?
How does DarioHealth address language barriers in healthcare?
What recent partnerships has DarioHealth announced?
What are the future plans for DarioHealth?
